A New Era for Peptide Therapy: What the FDA’s 2026 Reclassification Means for You
For the first time in years, the future of peptide therapy is looking brighter, more open, and more accessible than ever. On April 15, 2026, the FDA announced a major regulatory shift: 12 of the most widely studied and sought-after peptides are being moved out of restricted status. That includes powerhouse compounds like BPC-157, TB-500, […]
A New Era for Peptide Therapy: What the FDA’s 2026 Reclassification Means for You Read More »








